Open access
193
Views
12
CrossRef citations to date
0
Altmetric
Review
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
Michael A Via1 Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USACorrespondence[email protected]
, Himani Chandra2 Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, James J Peters VA Medical Center, New York, NY, USA
, Takako Araki1 Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA
, Matthew V Potenza3 Diabetes and Endocrinology, West Nyack, New York, NY, USA
& Maria Skamagas4 Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, NY, USA
Pages 43-48
|
Published online: 27 Sep 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.